No Data
Here's Why HARBIN GLORIA PHARMACEUTICALS (SZSE:002437) Can Manage Its Debt Responsibly
Yuheng Pharmaceutical: 2024 Annual Performance Forecast
Benign Growth For HARBIN GLORIA PHARMACEUTICALS Co., LTD (SZSE:002437) Underpins Its Share Price
Harbin Gloria Pharmaceuticals (002437.SZ): Currently, there are no plans for a spin-off listing on the Hong Kong stock market.
On December 19, Gelonghui reported that Harbin Gloria Pharmaceuticals (002437.SZ) stated on the investor interaction platform that the company's products, Annao Pills/Tablets, are unique essential pharmaceutical varieties of Traditional Chinese Medicine. The company will increase investment to enhance product competitiveness through improving product qualifications, increasing clinical medication guidelines, and professional academic promotions. Additionally, the company will actively seek differentiated products through independent research and development, cooperative development, mergers and acquisitions, and introduction, continuously enriching the company's product pipeline with high-end generic drugs and distinctive Chinese Patent Medicines, which have technical barriers. The company currently has no plans for a separate listing on the Hong Kong Stock Exchange.
Harbin Gloria Pharmaceuticals (002437.SZ): No plans to repurchase company shares.
Gelonghui, December 2nd | Harbin Gloria Pharmaceuticals (002437.SZ) announced that as of November 30, 2024, the company has not yet repurchased its shares through the dedicated securities repurchase account.
Harbin Gloria Pharmaceuticals (002437.SZ): Director Wang Dongxu has completed a shareholding reduction of 0.21 million shares.
On December 2, Gelonhui reported that Harbin Gloria Pharmaceuticals (002437.SZ) announced that on December 2, 2024, the company received a notification letter on the progress of the shareholding plan issued by Director Mr. Wang Dongxu. Mr. Wang Dongxu's shareholding plan has been fully implemented; he has cumulatively reduced holdings by 0.21 million shares, a reduction rate of 0.0092%.
The Market Doesn't Like What It Sees From HARBIN GLORIA PHARMACEUTICALS Co., LTD's (SZSE:002437) Revenues Yet As Shares Tumble 27%
